Pelvic Inflammatory Disease (PID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Pelvic Inflammatory Disease (PID) Market Outlook

Thelansis’s “Pelvic Inflammatory Disease (PID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pelvic Inflammatory Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pelvic Inflammatory Disease (PID) Overview

Pelvic Inflammatory Disease (PID) is an inflammatory condition affecting the upper genital tract in women, primarily involving the uterus, fallopian tubes, and ovaries. It is predominantly caused by an ascending infection, wherein pathogenic bacteria from the lower genital tract ascend to the upper tract. Among PID cases, approximately 85% are attributed to sexually transmitted bacteria. The most commonly implicated pathogens responsible for these infections are Neisseria gonorrhoeae and Chlamydia trachomatis. PID resulting from N. gonorrhoeae tends to be more severe than other causes. On the other hand, PID caused by chlamydia may often remain asymptomatic, leading to subclinical PID. Subclinical PID is concerning as it lacks apparent symptoms but can still have significant long-term repercussions. Infection in the upper genital tract leads to inflammation and subsequent damage, resulting in scarring, adhesions, and potential obstruction of the Fallopian tubes. The loss of ciliated epithelial cells along the fallopian tube lining due to scarring impairs ovum transport, leading to an increased risk of infertility and ectopic pregnancy. Furthermore, the presence of adhesions can contribute to chronic pelvic pain. The recommended first-line outpatient treatment for PID, according to CDC guidelines, involves a combination of doxycycline (100 mg orally twice a day for 2 weeks) and either ceftriaxone 500 mg intramuscularly for a single dose or cefoxitin 2 g intramuscularly with probenecid 1g orally for a single dose. Alternatively, another parenteral third-generation cephalosporin may be used. When considering PID as a possible diagnosis, it is essential to differentiate it from other conditions such as ectopic pregnancy, cystitis, ovarian torsion, endometriosis, ovarian cyst rupture, appendicitis, diverticulitis, traumatic injury, and pyelonephritis.

• It is estimated that approximately 10% to 15% of reproductive-age women have experienced at least one episode of PID. According to the CDC, more than 1 million women annually experience at least one Pelvic Inflammatory Disease (PID) episode. This disease leads to a substantial healthcare burden, resulting in approximately 2.5 million office visits and 125,000 to 150,000 hospitalizations annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: